This double-blind, randomized study involved 468 subjects with HbA1c levels ranging from 7.0% to 10.5% and stage 3 CKD who were receiving standard diabetes therapy, such as metformin, insulin, and/or sulfonylureas. This evidence concerns the gene INS and diabetes mellitus.